Julian Schulze Zur Wiesch to Antiviral Agents
This is a "connection" page, showing publications Julian Schulze Zur Wiesch has written about Antiviral Agents.
Connection Strength
0.158
-
Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol. 2018 02; 90(2):304-312.
Score: 0.068
-
Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes. J Infect Dis. 2019 07 19; 220(4):567-577.
Score: 0.019
-
Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. Gastroenterology. 2018 02; 154(3):515-517.e3.
Score: 0.017
-
Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort. Med Microbiol Immunol. 2017 Oct; 206(5):379-382.
Score: 0.017
-
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017 02; 17(2):215-222.
Score: 0.016
-
Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis. 2016 11 15; 63(10):1320-1324.
Score: 0.016
-
The Clinical Perspective on Hepatitis E. Viruses. 2019 07 05; 11(7).
Score: 0.005